Types of Tumors

Make selections below to learn more.

Click to Expand

Tumor Types
Tumor Types | BioOncology

Pipeline Molecules

The compounds and their uses mentioned on this website are investigational and have not been approved by the US Food and Drug Administration. Efficacy and safety have not been established. The information presented should not be construed as a recommendation for use. The relevance of findings in preclinical studies to humans is currently being evaluated. 

Phase I

  • Breast
  • Solid Tumor

Antibody-drug conjugate

(RG7882)b

 

  • Gastrointestinal
  • Gynecologic

Antibody-drug conjugate

(RG7986)b

 

  • Hematologic

Anti-CD20/CD3 TCB

(RG6026)

 

  • Hematologic

Anti-CD20/CD3 TDB

(RG7828)

 

  • Hematologic

Anti-CD40 MAb

(RG7876)

 

  • Solid Tumor

Anti-FAP-IL2v FP

(RG7461)

 

  • Genitourinary
  • Solid Tumor

Anti-OX40 MAb

(MOXR0916, RG7888)

 

  • Genitourinary
  • Solid Tumor

Anti-TIGIT

(MTIG7192A, RG6058)

 

  • Solid Tumor

BET inhibitor

(TEN-010, RG6146)e

 

  • Hematologic
  • Solid Tumor

Cergutuzumab amunaleukin (anti–CEA-IL2v)

(RG7813)

 

  • Solid Tumor

ChK1 inhibitor

(GDC-0575, RG7741)a

 

  • Solid Tumor

Codrituzumab (anti–glypican-3 MAb)

(GC33, RG7686)c

 

  • Gastrointestinal

Emactuzumab (anti–CSF-1R MAb)

(RG7155)

 

  • Solid Tumor

FAP-DR5 biMAb

(RG7386)

 

  • Solid Tumor

HIF1 alpha LNA

(RG6061)f

 

  • Gastrointestinal

LSD1 inhibitor

(RG6016)h

 

  • Lung

Pan-RAF inhibitor

(RG6185)i

 

  • Solid Tumor

Personalized Cancer Vaccine

(RG6180)j

 

  • Solid Tumor

PI3K inhibitor

(RG6114, GDC-0077)

 

  • Breast
  • Solid Tumor

Selective estrogen receptor degrader (SERD [2])

(GDC-0927/SRN-927, RG6047)d

 

  • Breast

Vanucizumab (anti–ANG2-VEGF biMAb)

(RG7221)

 

  • Solid Tumor

Phase II

  • Breast
  • Gastrointestinal
  • Genitourinary
  • Breast
  • Solid Tumor

Anti-OX40 MAb

(MOXR0916, RG7888)

 

  • Genitourinary

Codrituzumab (anti–glypican-3 MAb)

(GC33, RG7686)c

 

  • Gastrointestinal

Emactuzumab (anti–CSF-1R MAb)

(RG7155)

 

  • Solid Tumor

Phase III

  • Breast
  • Gastrointestinal
  • Genitourinary
  • Breast
  • Solid Tumor

aDeveloped in collaboration with Array BioPharma. bDeveloped in collaboration with Seattle Genetics. cDeveloped in collaboration with Chugai. dSeragon acquisition. eTensha acquisition. fSantaris acquisition. gDeveloped in collaboration with NewLink Genetics. hDeveloped in collaboration with Oryzon Genomics, S.A. iHanmi. jBioNtech.